Journals / Ortadoğu Tıp Dergisi / 2019 / Cilt: 11 - Sayı: 4

P53, HER2/neu, Bcl-2 and PCNA overexpression in ductal carcinoma in situ lesions of the breast and their role in progression to invasive carcinoma

Memenin duktal karsinoma in situ lezyonlarında P53, HER2/neu, Bcl-2 ve PCNA ekspresyonu ve bunların invaziv karsinoma progresyonda rolleri

Pages
490–496
Publication Date
2019-12-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These results contribute to define DCIS subtypes that have different biological behaviour.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Understanding proliferative activity and the changes in oncogenes and tumour supressor genes may be important to predict the ductal carsinoma in situ cases that have high probability of progression to invasive breast carcinoma.
📊
Key Findings & Data:In this study the correlation between p53, HER2/neu, bcl-2 and PCNA overexpression and progression of ductal carsinoma in situ were evaluated.Methods: We evaluated 20 ductal carsinoma in situ (group 1) and 20 ductal carsinoma in situ associated with invasive ductal carcinoma cases (group 2).
💡
Conclusion & Impact:These results contribute to define DCIS subtypes that have different biological behaviour.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Duktal karsinoma in situ · p53 · HER2/neu

Abstract

Objective: Understanding proliferative activity and the changes in oncogenes and tumour supressor genes may be important to predict the ductal carsinoma in situ cases that have high probability of progression to invasive breast carcinoma. In this study the correlation between p53, HER2/neu, bcl-2 and PCNA overexpression and progression of ductal carsinoma in situ were evaluated.Methods: We evaluated 20 ductal carsinoma in situ (group 1) and 20 ductal carsinoma in situ associated with invasive ductal carcinoma cases (group 2). We studied p53, HER2/neu, bcl-2 ve PCNA to cases immunohistochemically.Results: P53, HER2/neu and PCNA overexpression were higher in group 2 cases. But differences were not significant statistically (p>0,05). Bcl-2 overexpression was seen 36.8% in group 1, 70% in group 2 cases. The difference between two groups was significant statistically (p<0,05). In our study, also one of the important finding was that p53, HER2/neu, bcl-2 and PCNA overexpression were revealed 3 cases in group 2 at the same time but was not seen in any of group 1 cases.Conclusion: These findings showed that bcl-2 overexpression may be more important in progression of ductal carsinoma in situ to invasive ductal carcinoma, existing different pathways in development of invasive ductal carcinoma and revealing more than one of these changes in the same case may be more important in defining progression risk to invasive ductal carcinoma. These results contribute to define DCIS subtypes that have different biological behaviour.

Özet

Amaç: Proliferatif aktivitenin, onkogenlerde ve tümör süpresör genlerdeki değişikliklerin anlaşılması, duktal karsinoma in situnun invaziv meme kanserine gelişme ihtimalinin yüksek olduğu olguları belirlemede önemli olabilir. Bu çalışmada p53, HER2/neu, bcl-2 ve PCNA overekspresyonunun duktal karsinoma in situnun progresyonu ile ilişkisi değerlendirildi.Gereç ve Yöntem: Biz 20 duktal karsinoma in situ (grup 1) ve 20 invaziv duktal karsinoma birlikteliğinde duktal karsinoma in situ (grup 2) olgusunu değerlendirdik. Olgulara immünhistokimyasal yöntemler kullanılarak p53, HER2/neu, bcl-2 ve PCNA çalışıldı.Bulgular: Grup 2 olgularında p53, HER2/neu ve PCNA overekspresyonu daha yüksekti. Ancak farklar istatistiksel olarak anlamlı değildi (p>0,05). Grup 1 olgularının %36,8’inde, grup 2 olgularının %70’inde bcl-2 overekspresyonu izlendi. İki grup arasındaki bu fark istatistiksel olarak anlamlıydı (p<0,05). Çalışmamızda önemli bulgulardan biri de, p53, HER2/neu, bcl-2 ve PCNA overekspresyonunun aynı anda grup 2 olgularının 3’ünde izlenirken grup 1 olgularının hiçbirinde gözlenmemesiydi.Sonuç: Bulgular bize, bcl-2 overekspresyonunun duktal karsinoma in situnun invaziv duktal karsinomaya gelişim ihtimalinin yüksek olduğu olguları belirlemede daha değerli olabileceğini, invaziv duktal karsinoma gelişiminde farklı progresyon yollarının varolduğunu, preinvaziv evrede bu değişikliklerin birden fazlasının aynı olguda tespit edilmesinin invaziv duktal karsinomaya progresyon riskini belirlemede tek başlarına olduğundan daha değerli olabileceğini gösterdi. Bu sonuçlar farklı biyolojik davranışa sahip DKIS alt tiplerinin tanımlanmasına katkı sağlayacaktır.

🔖

Cite This Article

TAD, M., KULAÇOĞLU, S. (2019). P53, HER2/neu, Bcl-2 and PCNA overexpression in ductal carcinoma in situ lesions of the breast and their role in progression to invasive carcinoma. Ortadoğu Tıp Dergisi, Cilt: 11 - Sayı: 4, 490–496. https://ajindex.com/articles/30743

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Mercier I, Gonzales DM, Quann K, ve ark. CAPER, a novel regulator of human breast cancer progression. Cell Cycle 2014 Apr 15; 13(8): 1256-1264.
  2. Perez AA, Balabram D, Salles MA, Gobbi H. Ductal carcinoma in situ of the breast: correlation between histopathological features and age of the patients. Diagn Pathol. 2014; 9: 227-232.
  3. Terry G, Ho L, Londesborough P, Duggan C, Hanby A, Cuzick J. The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions. Br J Cancer 2007 Jan 15; 96(1): 110-117. Tot T. DCIS, cytokeratins and the theory of the sick lobe. Virchows Arch 2005; 447: 1-8.
  4. Gerber B, Müller H, Reimer T, Krause A, Friese K. Nutrition and lifestyle factors on the risk of developing breast cancer. Breast Cancer Res Treat 2003; 79(2): 265-276.
  5. Gerber B, Mylonas I. Reduction of the risk of breast cancer. Zentralbl Gynecol 2003; 125(1): 6-16.
  6. Pape-Zambito D, Jiang Z, Wu H, ve ark. Identifying a Highly-Aggressive DCIS Subgroups by Studying Intra-Individual DCIS Heterogeneity among Invasive Breast Cancer Patients. PLoS One. 2014; 9(6): e100488. Shang M, Zhang X, Liu X, ve ark. P16 and P53 Play Distinct Poles in Different Subtypes of Breast Cancer. PLoS One. 2013; 8(10): e76408. Menard S, Fortis S, Castiglioni F, Agresti R, Balsari A. HER-2 as a prognostic factor in breast cancer. Oncol 2001; 61: 67-72.
  7. Barlett JMS, Nofech-Moses S, Rakovitch E. Ductal carcinoma in situ of the breast: can biomarkers improve current management. Clin Chem 2014; 60(1): 60-67.
  8. Siziopikou KP, Khan S. Correlation of HER-2 gene amplification with expression of the apoptosis-suppressing genes bcl-2 and bcl-x-L in ductal carcinoma in situ of the breast. Appl Immunohistochem Mol Morphol 2005; 13: 14-18.
  9. Keohavong P, Gao WM, Mady HH, Kanbour-Shakir A, Melhem MF. Analysis of p53 mutations in cells taken from paraffin-embedded tisue sections of ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Cancer Lett 2004; 212(1): 121-130.
  10. Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B. Expression of Her2/neu, Steroid Receptors (ER and PR), Ki-67, and p53 in Invasive Mammary Ductal Carcinoma Associated with Ductal Cacinoma In Situ (DCIS) Versus Invasive Breast Cancer Alone. Anticancer Res 2005; 25: 1719-1724.
  11. Mommers ECM, Leonhart AM, Falix F, Michalides R, Meijer CJLM, Baak JP. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differantiation grade. J Pathol 2001; 194: 327-333.
  12. Mommers ECM, Va